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Relapsed chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and T-
prolymphocytic leukaemia (T-PLL) remain incurable with current chemotherapy. 
Mutations in genes involved in DNA damage response (DDR) are common in these 
disorders and may represent an opportunity to exploit Poly (ADP-ribose) polymerase 
(PARP) inhibitors that promote synthetic lethality and have shown marked efficacy in 
the treatment of solid tumours with homologous recombination repair (HRR) defects. 
 
We performed a phase I trial to determine the maximum tolerated dose (MTD) and 
safety of the PARP inhibitor olaparib in 15 patients with relapsed CLL, MCL or T-
PLL. The MTD of the capsule formulation was defined as 200mg twice daily (bd). 
The tablet formulation was tolerated at 100mg bd but the MTD was not defined. 
Myelosuppression was the main toxicity with grade ≥3 AEs observed in 66% of 
patients (grade ≥3 anaemia (5 Patients; 33%), thrombocytopenia (5 patients; 33%) 
and neutropenia (3 patients; 20%). The median survival of patients within the trial 
was 129 days. There appeared to be a trend towards longer treatment duration and 
increased survival in patients with DDR gene mutations. Olaparib may represent a 
useful therapy for patients with lymphoid tumours harbouring DDR alterations and 





Despite the array of therapeutic options in patients with chronic lymphocytic 
leukaemia (CLL), mantle cell lymphoma (MCL) and T-prolymphocytic leukaemia (T-
PLL), chemoresistance remains a major problem, particularly in advanced disease. 
Alkylating agents and purine analogues are the traditional chemotherapy agents 
used in the management of these malignancies and induce apoptosis in target cells 
through an ATM-p53 DNA damage response (DDR)-dependent pathway. As such, 
genetic alterations in the ATM-p53 DDR pathway represent an important mechanism 
of chemoresistance and it has been shown that defects and functional loss of DDR 
genes are associated with poor prognosis (Austen, et al 2005, Austen, et al 2007, 
Skowronska, et al 2012, Zenz, et al 2010, Zenz, et al 2011). 
 
In recent years, several agents that act independently of the ATM-p53 DDR pathway 
have become available, including immunotherapies and signalling inhibitors. These 
have markedly improved the clinical outcome for patients with CLL (Ghia and Hallek 
2014, Hallek 2013, Hallek, et al 2010) although ATM or TP53 gene abnormalities still 
impact on treatment response due to associated genomic instability which drives 
clonal evolution and promotes the selection of resistant (Byrd, et al 2013, Ouillette, et 
al 2010, Salin, et al 2008, Woyach, et al 2014). As such, there remains a need to 
develop new agents for the treatment of aggressive lymphoid tumours with DDR 
inactivation. 
 
The ataxia telangiectasia-mutated (ATM) protein plays a critical role in the DNA 
damage response to double strand breaks (DSBs) (Shiloh and Ziv 2013) and 
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phosphorylates multiple proteins to facilitate either cell cycle arrest and DNA repair 
or apoptosis. Loss of ATM function in lymphoid tissues leads to the propagation of 
cells which harbour erroneously resolved DSBs that are associated with increased 
risk of malignant transformation. Indeed, individuals with inherited mutations in both 
ATM alleles have a highly increased risk of developing a wide range of B- and T-cell 
lymphoid malignancies (Stankovic, et al 1998). Somatic ATM mutations have also 
been found in a range of sporadic lymphoid tumours including B-CLL, MCL and T-
PLL (Gronbaek, et al 2002, Stilgenbauer, et al 1997, Vorechovsky, et al 1997). 
These may occur in the form of monoallelic intra-chromosomal deletions of 11q or as 
biallelic inactivation through the combination of 11q deletion and mutation of the 
remaining ATM allele. 
 
One emerging strategy to target cells in which ATM function has been lost is the 
approach of ‘synthetic lethality’, which exploits the fact that when tumour cells are 
impaired in one DSB repair mechanism they become critically dependent upon 
alternative pathways (Bouwman and Jonkers 2012, Shaheen, et al 2011). Poly 
(ADP-ribose) polymerase (PARP) plays a central role in single strand break (SSB) 
repair and when the activity of this enzyme is inhibited unrepaired SSB lesions are 
converted into DSBs during DNA replication. The resolution of these DSBs 
subsequently requires activation of homologous recombination repair (HRR) 
proteins, such as BRCA or ATM. PARP inhibitors have therefore been used to target 
tumour cells that carry mutations in genes such as BRCA or ATM and demonstrate 
an HRR-deficient phenotype. In relation to haemopoietic tumours, we have 
previously demonstrated the utility of PARP inhibition as a targeted therapy for ATM-
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defective CLL and MCL, both in vitro and in in vivo pre-clinical xenograft models 
(Weston, et al 2010). 
 
Olaparib is an oral PARP inhibitor that has been used widely in patients with solid 
tumours such as BRCA1/2-mutated ovarian, prostate and gastric cancers (Bryant, et 
al 2005, Kaufman, et al 2015, Mateo, et al 2015). It is well tolerated and 
demonstrates significant activity both as a single agent and in combination with 
chemotherapy (Bang, et al 2015, Bendell, et al 2015, van der Noll, et al 2015). In 
contrast to solid tumours, there is limited data for PARP inhibitors in haematological 
malignancies. Mild myelosuppression has been observed during the use of olaparib 
in patients with solid tumours, particularly in combination with chemotherapy (Bang, 
et al 2015, Bendell, et al 2015, van der Noll, et al 2015). Myelosuppression may 
therefore act as a potentially limiting factor in the treatment of haematological 
malignancies and an early phase trial in such malignancies is required to assess 
safety and the maximum dose that can be tolerated. 
 
Here we report the results of a phase I trial addressing the safety of the PARP-
inhibitor olaparib in patients with relapsed CLL, T-PLL or MCL. Particular focus was 





Materials and Methods 
 
Patient population, trial design, treatment and outcome measures 
The Parp Inhibitor in relapsed Chronic Lymphocytic Leukaemia (PICCLe) trial was 
designed as a single arm, multi-centre, open label phase I/II trial although the phase 
II trial did not commence. Eligible patients had relapsed CLL, MCL or T-PLL and 
were not considered to be appropriate for further conventional treatment. Importantly 
for the phase I trial, patients lacking a confirmed chromosome 11q deletion or an 
ATM mutation were not excluded. Further inclusion criteria involved an ECOG 
performance status of ≤ 2, and an estimated life expectancy of more than 16 weeks. 
Important exclusion criteria incorporated persisting (>8 weeks) severe pancytopenia 
caused by previous therapy rather than disease (neutrophils <0.5 x 109/L or platelets 
<50 x 109/L) and concomitant treatment with strong CYP34A inhibitors. Full eligibility 
criteria are given in the supplementary material (Figure S1). The clinical trial was 
approved by the UK National Research Ethics Service (NRES) Committee West 
Midlands - Solihull and performed in accordance with local ethical guidelines. Written 
informed consent was obtained from all patients in accordance with the Declaration 
of Helsinki. 
 
Phase I trial was designed as a conventional dose escalation trial (cumulative 3+3 
design) the primary objective being the assessment of safety and maximum tolerated 
dose (MTD) (Figure 1). Successive cohorts of patients (3 patients per cohort) were 
treated with a fixed dose of olaparib. The MTD was defined as the highest dose with 
observed dose-limiting toxicities, (DLTs) of 0 or 1 out of 6 patients, where the next 
higher dose has at least 2 observed DLTs out of up to 6 patients. The initial 3 
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cohorts (9 patients) received the original capsule formulation of olaparib. However, 
during the trial AstraZeneca developed a tablet formulation to improve drug loading 
and bioavailability and reduce the number of tablets required to achieve the desired 
dose. Consequently, a further 2 cohorts received the new tablet formulation (6 
patients). A starting dose of 200 mg bd in capsule formulation and 100 mg bd for 
tablet formulation was specified in the protocol and was intended to be given until 
progression (Figure 1).  
 
Safety and tolerability of olaparib was assessed using the Common Terminology 
Criteria for Adverse Events Version 4.0) (CTCAE v4.0). The number of patients 
experiencing toxicities is reported by dose level, category and grade of severity 
(Table 3). The DLT assessment period spanned 8 weeks from treatment initiation. 
Only patients that completed 8 weeks of treatment were evaluable, unless they 
experienced a DLT which was considered as an event. A DLT was defined as any 
drug related non-haematological toxicity of: grade ≥3, with the exclusion of nausea, 
vomiting and diarrhoea unless not ameliorated by symptom directed therapy, or 
grade 4 neutropenia lasting ≥7 days or grade 4 thrombocytopenia with platelets 
<10x109/L despite ≥7 days transfusion support. Patients whose DLT outcome could 
not be assessed due to death-caused withdrawal or disease progression during the 
8 week period were replaced. 
 
Molecular analysis 
Specific primers for targeted deep sequencing of ATM (exons 4-65), SF3B1 (exons 
13-16), TP53 (exons 4-10), BIRC3 (exons 2-9), and MyD88 (exon 5) were designed 
with the D3 Assay Design web-based tool (https://www.fluidigm.com/assays) (Table 
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SI). The Access-Array system (Fluidigm) was used to generate amplicon libraries 
from 15-50 ng genomic DNA, for each sample extracted using the QIAamp DNA 
blood mini kit (Qiagen, Manchester, UK). PCR products were barcoded, pooled, 
purified using Ampure XP beads (Beckman Coulter, High Wycombe, UK), quantified 
by 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) then paired-end 
sequenced using a 500-cycle kit (2x250) on the  MiSeq platform (Illumina, 
Cambridge, UK). Typically, several thousand reads were captured per amplicon. 
Generated files were quality filtered by Trimmomatic (v0.3), retaining reads with a Q-
score >30, in a 4 base sliding window followed by primer removal using cutadapt 
(v1.2.1). Resultant sequencing reads were aligned with the Human Reference 
Genome (hg19, GRCh37) using the Burrows-Wheeler Aligner-MEM algorithm (BWA-
MEM, v0.7.5). Coverage was analysed using the Bedtools (v2.17) API and cstom 
Python script. Appropriate read group information was added by Picard (v1.128) and 
realigned with the Genome Analysis Toolkit (GATK, v2.7.1) IndelRealigner tool. 
Variant calling was performed by UnifiedGenoTyper (GATK), Pindel (v0.2.5a1) and 
Platypus (v0.7.9). Resultant files were annotated using Annovar (July 2013 release), 
results merged and inter-run frequency calculated by a custom Python script58. A 
selected number of mutations were validated either by Sanger sequencing, if allelic 
frequency exceeded 20%, or allele specific PCR if below 20%. NOTCH1 (exon 34) 
analysis was performed by Sanger sequencing with an annealing temperature of 
60°C using primers designed with Primer3 via NCBI Primer-BLAST 






No formal statistical analysis was performed. Data were summarised using 
descriptive statistics (number of patients, median, minimum and maximum) for 
continuous variables and frequency and percentage for discrete variables. Data are 
presented for all patients who started treatment. 
 
Efficacy analyses on Overall Survival (OS) were not originally planned for the Phase 
I part of the trial, but these had been summarized as the trial did not proceed into 
Phase II. OS was defined in days from the start of treatment to the date of death as a 
result of any cause. Patients without a documented date of death will be censored at 
the last date a patient is known to be alive or lost to follow-up. Median survival time 
was calculated using Kaplan–Meier methodology (where appropriate). This was 
reported as a whole group, by formulation and by mutation status along with 
treatment duration which was also reported by mutation status. All analyses were 
performed using R software (Team 2015). However, as this was a phase I trial with a 
heterogeneous patient population in terms of diseases, previous lines of therapy, co-
morbidities and variable doses of olaparib, the efficacy analyses were only 










A total of 15 patients with relapsed CLL (n=9), MCL (n=4) or T-PLL (n=2) were 
enrolled and evaluated (Table 1). The median age of patients was 69 years (range 
53–77) with male/female ratio of 2/13. The median number of previous lines of 
therapy was 3 (range 1-7).  
 
Safety and Tolerability 
The median duration of olaparib treatment was 71 days with an interquartile range of 
26 – 93 days. Myelosuppression was the most common haematological grade 3-4 
toxicity and was seen in 8 patients. However as many of the patients had low white 
blood counts due to pre-existing disease the contribution of olaparib to the observed 
myelosuppression was not entirely clear for all patients. Of the 6 patients dosed at 
200mg bd (capsule) 3 patients experienced grade ≥3 AEs, all 3 patients who were 
dosed at 400mg bd (capsule) experienced at least 1 grade ≥3 AE. For the tablet 
formulation of olaparib, from those 6 patients dosed at 100mg bd 4 patients 
experienced grade ≥3 AEs (Table 3). 
 
Overall, both formulations of olaparib were generally well tolerated in our trial of high 
risk patients. The most common adverse events (AEs) were anaemia (66%), 
followed by decreased platelet count (53%), fatigue (53%), nausea (33%) and 
decreased neutrophil count (33%) (Table 3). Grade ≥3 AEs were reported for 10 
patients (66%) with the most common of these again being anaemia and decreased 
platelet count in 5 patients (33%) each, followed by decreased neutrophil count in 3 
patients (20%) (Table 3). 
 
Maximum Tolerated Dose 
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The second primary objective of the Phase I component was to define the MTD of 
olaparib in this patient group. The original capsule formulation of olaparib was 
changed to an oral tablet during the trial and the MTD was therefore assessed 
separately for each of these formulations (Figure 1). 
 
Six patients received olaparib capsules at the starting dose of 200mg bd and only 
one patient developed a DLT (Figure 1, Table 2). This DLT was due to development 
of grade 4 thrombocytopenia within 2 weeks of treatment initiation and occurred in 
an MCL patient with bone marrow involvement, who was heavily pre-treated and 
experienced relapse from an allogeneic stem cell transplant. Three patients went on 
to receive the higher dose of 400mg capsules bd and all developed DLTs which 
were possibly attributable to olaparib within 6 weeks of treatment initiation (Figure 1, 
Table 2). These DLTs were evident as grade ≥3 maculo-papular rash, grade ≥3 
anorexia or weight loss and a grade 4 thrombocytopenia, in a patient who had pre-
existing thrombocytopenia. The MTD for olaparib capsules was therefore defined as 
200mg capsules bd. 
 
The tablet formulation of olaparib was introduced at a treatment dose of 100mg bd 
and was administered to 6 patients (Figure 1, Table 2). One patient developed a fatal 
DLT which presented as an infective episode, renal failure (acute kidney injury) and 
bleeding with a high International Normalised Ratio (INR) on warfarin (Figure 1, 
Table 2). A further patient failed to complete the course due to disease progression. 
Unfortunately, at this point recruitment ceased and we were therefore unable to 




Nine deaths were observed during the trial period. The median OS from the start of 
treatment for all 15 patients was 129 days (Figure 2a). The median OS for patients 
treated with capsules (106 days) was not dissimilar to that for patients treated with 
tablets (129 days) (Figure 2b). 
 
2. Molecular characteristics of tumours 
 
Peripheral blood mononuclear cells were obtained prior to olaparib treatment from all 
15 patients enrolled in this trial. These were subjected to deep sequencing of 6 well-
established CLL ‘driver’ genes: ATM, TP53, BIRC3, SF3B1, NOTCH1 and MyD88. 
Twelve patients (80%) had evidence of a mutation in at least one of the analysed 
genes (Figure 3a, Table S2). A further patient, TNO13, presented with monoallelic 
ATM loss due to an 11q deletion (Figure 3a, Table 2). It has recently been reported 
that tumours that carry SF3B1 gene alterations have similar functional 
consequences to that of ATM loss, indicating that SF3B1 is itself involved in the DNA 
damage response pathway (Te Raa, et al 2015). This justified our strategy to 
observe ATM and SF3B1 mutant tumours as a single group with defective DDR. Of 
note, mutations in either ATM or SF3B1 were seen in 9 patients (60%; Figure 3a, 
Table 2). Patient TNO4 exhibited bialleic ATM loss by virtue of the co-presence of 
the UK founder ATM mutation c.7271T>G with an 11q deletion, both present at 
>90% frequency. Interestingly this patient also harboured a NOTCH1 mutation, 




To assess how tumour mutation status impacted on the clinical outcome of patients 
in the trial we initially assessed genotype in relation to ‘time on treatment’. Treatment 
duration ranged from 8 to 133 days with a median of 83 days in patients whose 
tumours carried mutated DDR genes (within ATM or SF3B1; ‘mutated DDR’) 
compared to 37.5 days in those lacking such alterations (‘unmutated DDR’) (Figure 
3b). A longer median survival time of 192 days was also seen in patients with 
‘mutated DDR’ genotype compared to 89 days in the ‘unmutated DDR’ group (Figure 
3c). Our preliminary observations, in a small cohort (n=15), suggest that aberrations 
in the ATM pathway may confer longer treatment duration and overall survival even 




Olaparib has demonstrated clinical efficacy in many studies and is an approved 
indication for the treatment of patients with deleterious or suspected germline BRCA-
mutated advanced ovarian cancer. Tolerability has generally been good and the 
main toxicities seen in patients with solid tumours have been low grade GI toxicity 
(nausea, vomiting), fatigue and anaemia. However, combining olaparib with other 
myelotoxic drugs has shown myelosuppression in patients with solid tumours (Bang, 
et al 2015, Bendell, et al 2015, van der Noll, et al 2015) and emphasises the need to 
define the optimal dose in patients with haematological tumours as a single agent or 
in any potential combination. 
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The phase I trial described here tested olaparib as a single agent in a heavily pre-
treated group of patients with lymphoid tumours and defined the maximum tolerated 
dose as 200mg capsules taken bd. In contrast to solid tumours where use of a single 
agent 400mg bd capsule formulation is generally well tolerated the same dose led to 
3 types of DLT (rash, thrombocytopenia, anorexia) in patients with haematological 
malignancies. 
 
Although olaparib was initially available as a capsule, the tablet formulation of 300mg 
bd is now used in most studies. This change in formulation, which occurred during 
the trial, limited the number of patients who could be recruited to the trial but the 
findings still provide important preliminary information. We observed that, similarly to 
its use in the treatment of solid tumours, olaparib was generally well tolerated in 
patients with lymphoid malignancies but was associated with the development of 
myelosuppression in patients with an extensive history of pre-treatment or bone 
marrow involvement. However, it is important to note that many of the patients 
enrolled on the trial had very advanced disease following multiple lines of therapy. It 
was therefore difficult to establish with confidence whether toxicity was related to 
olaparib or disease progression and this reflects the challenge of testing novel drugs 
in patients who have received multiple lines of therapy. The trial also highlighted a 
number of major challenges associated with early phase clinical trials. Firstly, the 
unforeseen change from capsule to tablet formulation of olaparib led to a major 
suspension of recruitment for almost a year (351 days). Even though the MTD of 
olaparib was obtained for the capsule formulation after 9 evaluable patients, it was 
no longer relevant due to the very different pharmacokinetic properties of capsule 
and tablet formulation and competing trials prevented us from completing 
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recruitment. The latter factors were unavoidable although in retrospect the trial 
design was also a factor that impacted on slow recruitment. The conventional ‘3+3’ 
recruitment design suffered from the requirement that all 3 patients in a cohort had to 
complete 8 weeks on the trial in order to assess the occurrence of DLT. In addition, 
time had to be factored in for safety data to be gathered and reviewed by the safety 
review committee before opening of the next cohort at the next dose. Hence there 
was an average suspension of recruitment between cohorts of up to 11 weeks and in 
retrospect, given a very good initial recruitment, a more efficient model-based design 
such as a modified time-to-event Continual Reassessment Method (Cheung 2011, 
Cheung and Chappell 2000) could have allowed for more flexible cohort sizes as 
well as shorter suspension periods between cohorts whilst ensuring safety. This 
greater efficiency in recruitment would have meant that the trial could have been 
completed in a shorter period of time. In recent years there has been increasing 
interest in the use of such efficient model-based designs as they offer the potential to 
treat more patients at optimal doses, reduce the number of patients who receive sub-
therapeutic doses and provide greater accuracy in attaining the MTD (Mussai, et al 
2014). However these designs are more resource intensive and require specialist 
software that was not available when this trial was first planned in 2008 (Jaki 2013). 
 
The greatest efficacy of PARP inhibitors has been seen in tumours which carry 
genetic defects in homologous recombination and as such we examined tumour 
material for the presence of mutations within several CLL ‘driver’ genes including 
ATM and SF3B1. This suggested an interesting trend towards improved efficacy of 
olaparib in patients whose tumour was predicted to have a defective DNA damage 
response due to mutation within ATM or SF3B1. This was observed as an increased 
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time on treatment and increased survival time, although larger trials would be 
required to confirm this observation. In addition, it is possible that PARP inhibition 
could provide benefit in patients in whom no impairment of the DNA damage is 
observed within tumour cells as a bulk population. In particular, the importance of 
clonal heterogeneity and tumour evolution are recognised increasingly in 
haematological malignancies and it is likely that many patients harbour a minor 
tumour subclone with mutations within DNA damage response genes. In such a 
setting the incorporation of olaparib into standard chemotherapy regimens may act to 
prevent the selection of this potentially resistant subpopulation. 
 
In summary, this early phase trial demonstrates that single agent olaparib is tolerable 
in patients with haematological malignancies although myelosuppression appears to 
be an important issue. Future studies would be needed to better define the optimal 
dosage but this early data suggest that olaparib could have potential clinical utility in 
patients with DDR defective and clinically refractory haematological malignancies. 
  
 18 
Acknowledgements and Funding: 
We acknowledge the support of Bloodwise. Olaparib was provided free of charge 
from AstraZeneca. CY was funded by CRUK/12/046. We would like to thank Sam 
Clokie and Ania Skowronska for their help with NGS and bioinformatics and all the 
patients and clinical staff for their participation.  
 
Conflict of Interest: 
The authors report no potential conflicts of interest. 
 
Author Contributions: 
G.P., C.Y. and T.S., designed the research and G.P was Chief Investigator for the 
trial. MG, MD, CF, DO, AP, EM, SD, DA. AB, PH, GF, SR were Principal 
Investigators for the trial.  C.Y and D.S conducted the statistical analyses. G.P., C.Y., 
C.O., D.S. and T.S. interpreted the results. G.P., C.Y., D.S., C.O., R.B., P.M. and 







Figure 1. Enrollment, Sequential assignment and Dose Limiting Toxicities 
experienced by patients for Capsule and Tablet formulations  
 
Figure 2. Overall survival of patients enrolled on the PICCLe trial was 
unaffected by treatment formulation 
Kaplan Meier curves depicting OS of (Figure 2a) all 15 patients and (Figure 2b) 
stratified according to the treatment formulation using 200 mg or 400 mg capsule 
(n=9) or 100 mg tablet (n=6) with the number of patients at risk at different time 
points noted. Median OS was 129, 106 and 129 days; respectively. 
 
Figure 3. Patients enrolled on the PICCLe trial with tumours harbouring CLL 
driver mutations which play a role in DDR have a slightly elongated time to 
olaparib discontinutation and longer overall survival 
Heatmap depicting the distribution and allelic frequency of genetic alterations in 6 
CLL driver genes: ATM, SF3B1, TP53, BIRC3, NOTCH1 and MyD88, aligned 
according to time on olaparib treatment. Patients who sustained treatment with 
olaparib for at least 2 months are enriched for the mutated DDR genes, ATM and/or 
SF3B1. *Indicates the presence of an 11q deletion, NOTCH1 AF estimated from 
Sanger sequencing (Figure 3a). Kaplan-Meier curves depicting (Figure 3b) time to 
treatment discontinuationt and (Figure 3c) OS for patients according to the presence 
(n=9) or absence (n=6) of a DDR defect with the number of patients at risk at 
different time points noted. There is a non-significant trend towards elongation of 
both treatment duration (83 vs 37.5 days) and OS (192 vs 89 days) for patients 
harbouring mutation(s) of the DDR genes, ATM and SF3B1 (DDR mutated) vs those 








Table 1:  Baseline Summary Statistics of Patient Characteristics for both the 
Capsule and Tablet Formulations of Olaparib 
This table contains counts and percentages for categorical patient characteristics 
(e.g. Gender, Disease) and contains the Mean (sd), Median and Range for 
continuous Patient Characteristics at baseline (e.g. Time from Diagnosis, Age). 
 
Table 2: Trial Patient Summary 
This table provides information at the patient level on both patient characteristics 
(e.g. age, gender, disease) and key trial information (e.g. DLT status, Discointuation 
reason and mutation status). 
 
Table 3: Adverse events: all grades and grade >= 3  
Details the number of patients who have experienced adverse events categorised 
using the CTCAE system. The number of patients are provided for experiencing a 
particular event at any grade and grade ≥ 3 for each dose given to patients for both 
the capsule and tablet formulations.      
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